Since previous studies have demonstrated the effectiveness of liquid biopsy in detecting EGFR, PIK3CA, BRAF, KRAS, HER2, ALK, PDGFR, and KIT mutations, liquid biopsy procedures may replace tumor tissue biopsy for detecting these mutations in the future [6, 8, 44, 54, 55]. This evidence concerns the gene ERBB2 and neoplasm.